Clinical Outcomes Data
Real-time analytics from MindScape Retreat's Alcohol Dependency Protocol program. Aggregated across 65 patients with validated clinical assessments tracked over 7 timepoints.
The live analytics dashboard below aggregates longitudinal outcome data from MindScape Retreat's 65-patient alcohol dependency cohort, tracking clinical trajectories across seven validated assessment timepoints from admission through 90-day follow-up. Because alcohol withdrawal involves distinct neurological risks that opioid withdrawal does not, including tonic-clonic seizure potential, autonomic dysregulation, and delirium tremens. the assessment instruments used in this cohort differ fundamentally from those applied in opioid dependency studies. The primary clinical instruments are the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised) and the AUDIT (Alcohol Use Disorders Identification Test), which together capture both acute withdrawal severity and the pattern of harmful alcohol use that sustains dependency beyond the initial cessation period.
Unlike opioid-specific instruments such as COWS or SOWS, which measure predominantly adrenergic and autonomic withdrawal signs, the CIWA-Ar assesses ten neurological domains, including perceptual disturbances and orientation. that reflect the GABAergic and glutamatergic mechanisms uniquely disrupted by chronic alcohol exposure. The dashboard tracks how these alcohol-specific trajectories respond to ibogaine's multi-receptor mechanism across the full cohort.
The trajectories above reveal a pattern consistent with ibogaine's GABAergic and glutamatergic mechanism of action in alcohol dependency. CIWA-Ar scores drop sharply within the first 72 hours following ibogaine administration. a trajectory that reflects ibogaine's NMDA receptor antagonism blunting the glutamate rebound that drives the most dangerous phase of alcohol withdrawal. The craving reduction curve follows a parallel but slightly delayed arc, consistent with the progressive normalization of dopaminergic reward circuitry through ibogaine's BDNF and GDNF upregulation.
A clinically important feature of this cohort is the relationship between withdrawal severity and the phenomenon of alcohol kindling. the progressive intensification of withdrawal syndromes across successive detox episodes due to glutamate receptor sensitization. Patients in this cohort with prior failed detox attempts showed higher baseline CIWA-Ar scores than first-time detox patients, confirming kindling as a measurable factor in this population. Ibogaine's NMDA modulation appears to interrupt this sensitization cycle rather than simply suppressing a single withdrawal episode, which may explain the sustained abstinence rates observed at 90-day follow-up compared to conventional pharmacological detox approaches.
Study Overview
65 Patients. 8.3 Years Average Dependency. One Neurobiological Reset.
This cohort study enrolled 65 patients presenting with clinically confirmed alcohol use disorder (AUD) at the severe range. Participants averaged 8.3 years of active alcohol dependency at enrollment and had an average of 2.4 prior treatment attempts including inpatient rehabilitation, medically-supervised detox, naltrexone, and Alcoholics Anonymous participation.
Seventy-three percent of the cohort presented with poly-substance profiles. primarily alcohol combined with cocaine or stimulant use. reflecting the clinical reality that alcohol dependency rarely exists in isolation and that effective treatment must address the underlying neurological drivers rather than a single substance in isolation.
Primary outcome measures included the Clinical Institute Withdrawal Assessment for Alcohol Revised (CIWA-Ar), the Alcohol Use Disorders Identification Test (AUDIT), and a Visual Analog Scale for Craving (VAS Craving). Weekly alcohol consumption units were tracked via self-report at 30, 60, and 90-day follow-up intervals. Secondary outcomes included sleep quality, depressive symptom load, and patient-reported quality of life.
The chart below presents cohort-averaged scores on the two primary clinical instruments used in this study: the CIWA-Ar and AUDIT. The CIWA-Ar is a 10-domain observer-rated scale covering nausea and vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache or fullness in the head, and clouding of sensorium. It is scored from 0 to 67, with scores below 8 indicating absent or minimal withdrawal, 8 to 15 indicating mild withdrawal, 16 to 20 indicating moderate withdrawal, and scores above 20 indicating severe withdrawal with significant risk of tonic-clonic seizure and delirium tremens. The AUDIT, developed by the World Health Organization, measures the full spectrum of harmful alcohol use across 10 items including consumption frequency, binge drinking, dependence symptoms, and social harm, scored from 0 to 40.
At baseline, this cohort's mean CIWA-Ar of 24 placed the average patient in the severe withdrawal range. a threshold where standard clinical guidance recommends inpatient monitoring due to seizure risk. The mean AUDIT score of 28 situates the cohort in the "likely dependence" category, well above the threshold of 20 that WHO defines as indicating probable alcohol dependence requiring specialized intervention.
Alcohol Withdrawal. CIWA-Ar & AUDIT Scores. Baseline vs. Post-Treatment
CIWA-Ar measures alcohol withdrawal severity (0 to 67). AUDIT measures harmful alcohol use (0 to 40). Both represent cohort averages at baseline and post-treatment assessment. Lower scores indicate clinical improvement.
Source: MindScape Retreat Alcohol Dependency Cohort Study (n=65), post-treatment assessment.
The CIWA-Ar and AUDIT data above capture the clinical and diagnostic dimensions of alcohol dependency. the acute withdrawal syndrome and the pattern of harmful use, but they do not directly measure the subjective craving experience that drives relapse in the weeks and months following detox. The following chart addresses this gap by presenting the cohort's Visual Analog Scale for Craving (VAS Craving) alongside weekly alcohol consumption units, together, the two most behaviorally predictive indicators of long-term abstinence. Where the CIWA-Ar measures what the body does when alcohol is removed, the VAS Craving measures what the mind continues to demand, and it is this craving dimension that conventional detox most consistently fails to resolve.
Craving & Consumption Measures. Baseline vs. Post-Treatment
VAS Craving is measured on a 0 to 100 scale (higher = stronger craving). Weekly Units reflects standard alcohol units consumed per week. Both represent cohort averages. Lower scores indicate clinical improvement.
Source: MindScape Retreat Alcohol Dependency Cohort Study (n=65), 90-day follow-up assessment.
Taken together, the CIWA-Ar and AUDIT data from the first chart and the VAS Craving and weekly consumption data from the second present a convergent clinical picture: ibogaine simultaneously resolves the acute withdrawal syndrome and attenuates the chronic craving architecture that sustains alcohol relapse. The 82% reduction in CIWA-Ar scores reflects neurochemical stabilization of the GABAergic and glutamatergic systems disrupted by alcohol dependence, while the 85% reduction in VAS Craving and 93% reduction in weekly units consumed reflect the interruption of the mesolimbic dopamine pathways through which alcohol maintains its motivational grip. Together, these two dimensions address the principal reasons conventional treatment fails: detox without craving resolution invariably leads to relapse once the acute phase passes.
The 90-day abstinence rate of approximately 90% in this cohort, observed against a backdrop of an average 2.4 prior treatment failures, reflects what becomes clinically possible when both the neurological and motivational dimensions of alcohol dependency are addressed within a single treatment framework. The methodology that produced these outcomes is detailed in the section below.
Prospective Observational Cohort Study
Study Design
Prospective, single-center observational cohort with 90-day longitudinal follow-up. Stratified analysis by substance profile: alcohol-only (n=18, 27%) and poly-substance alcohol + cocaine/stimulant (n=47, 73%). Written informed consent. No placebo control, ethically precluded given active withdrawal management requirements.
Inclusion Criteria
Adults aged 21 to 65 with AUD diagnosis (DSM-5 severe range). Minimum 2-year active alcohol dependency. CIWA-Ar baseline ≥ 10 (moderate withdrawal risk). Cardiac clearance (QTc < 450ms, sinus rhythm). Hepatic function: Child-Pugh Class A or B (Class C excluded). At least one prior treatment attempt documented.
Assessment Instruments
Primary: Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar, 0 to 67). Secondary: Alcohol Use Disorders Identification Test (AUDIT, 0 to 40), VAS Craving (0 to 100), weekly standard alcohol units consumed. Supplementary: PHQ-9 for depressive comorbidity, Pittsburgh Sleep Quality Index (PSQI), patient-reported quality of life.
Assessment Schedule
Baseline (admission), daily CIWA-Ar during inpatient phase, 72h post-ibogaine, Day 7, Day 14 (discharge), Day 30, Day 60, Day 90 follow-up. Weekly alcohol consumption tracked via timeline follow-back method at each follow-up. Collateral verification from family/sponsor where available.
Poly-Substance Subgroup
Pre-specified subgroup analysis for the 73% poly-substance cohort (alcohol + cocaine/stimulants). Cocaine use assessed via self-report and urine toxicology at follow-up timepoints. Between-group comparison (alcohol-only vs. poly-substance) across all primary endpoints using independent samples t-test.
Safety Monitoring
Benzodiazepine bridge protocol for patients with CIWA-Ar > 15 or seizure history. Continuous cardiac telemetry during ibogaine administration. Hepatic panels (LFTs) at baseline, Day 7, Day 14, and Day 30 given chronic alcohol's hepatotoxic burden. Seizure precautions maintained through Day 5 post-cessation.
Mechanism of Action
GABA Normalization, Glutamate Rebalancing, and the End of Compulsive Drinking.
Alcohol dependency is primarily a disorder of GABAergic and glutamatergic dysregulation. Chronic alcohol use suppresses glutamate activity and upregulates GABA signaling to maintain neurochemical equilibrium. When alcohol is removed, this adaptation produces the dangerous withdrawal syndrome driven by glutamate rebound. characterized by seizure risk, autonomic instability, and the crushing craving that makes abstinence so difficult to sustain.
Ibogaine addresses this dysregulation through a multi-receptor mechanism that no other intervention replicates. Acting as an NMDA receptor antagonist, ibogaine blunts glutamate rebound during and after withdrawal, reducing both the severity and the neurological 'craving signature' produced by glutamatergic hyperactivity. Simultaneously, ibogaine's sigma-1 receptor agonism promotes neurotrophic factor release. particularly BDNF and GDNF. facilitating the normalization of dopaminergic reward circuitry that chronic alcohol exposure has chronically dysregulated.
Ibogaine's 5-HT2A agonist activity provides an additional therapeutic dimension specific to compulsive alcohol use. Serotonergic dysregulation drives the impulsive, habitual quality of heavy drinking. the loss of conscious control over intake. Ibogaine's serotonergic rebalancing, combined with the window of psychological insight produced during the treatment experience, allows patients to disengage from the compulsive behavioral loop in a way that willpower, counseling, and pharmacotherapy alone cannot achieve.
Dual Diagnosis Findings
The Poly-Substance Cohort: Alcohol + Cocaine and Stimulant Outcomes
Seventy-three percent of enrolled patients presented with alcohol combined with concurrent cocaine or stimulant use disorder. This poly-substance subset demonstrated outcomes comparable to, and in some measures superior to, the alcohol-only subgroup. a finding consistent with ibogaine's broad-spectrum action across multiple substance-specific dependency mechanisms.
For the alcohol-cocaine subgroup, ibogaine's interruption of cocaine craving through kappa-opioid receptor and dopamine transporter modulation produced a dual-substance reset from a single treatment session. Patients who had previously been unable to address alcohol and cocaine simultaneously due to cross-dependency and mutual trigger reinforcement were able to disengage from both patterns during the post-treatment integration window.
These dual-diagnosis findings have direct clinical implications. Patients who present with alcohol dependency alongside stimulant use should not be excluded from ibogaine evaluation on account of polydrug complexity. Our data suggest that co-occurring stimulant use does not diminish alcohol-related outcomes and may in some cases benefit from the same neurobiological reset that alcohol dependency requires.
Principal Findings From 65-Patient Alcohol Cohort
Approximately 90% of patients maintained alcohol abstinence at 90-day follow-up (confirmed via self-report, collateral verification, and consumption tracking). This compares favorably to naltrexone's published 30 to 40% reduction in heavy drinking days and acamprosate's 36 to 45% abstinence rates in randomized controlled trials.
CIWA-Ar scores decreased 82% from baseline (24.1 ± 5.3 → 4.3 ± 2.7, p < 0.001, Cohen's d = 4.1). The withdrawal severity reduction was clinically meaningful, crossing the threshold from moderate-severe withdrawal (seizure risk range) to minimal/no withdrawal within 72 hours of ibogaine administration.
AUDIT scores decreased 79% (28.4 → 6.0), transitioning from the 'harmful use/likely dependence' range (> 20) to the 'low-risk drinking' range (< 8). This magnitude of AUDIT score change is consistent with genuine behavioral remission rather than temporary withdrawal suppression.
Poly-substance patients (n=47, 73% of cohort) achieved outcomes statistically indistinguishable from the alcohol-only subgroup across all primary endpoints (p > 0.05 for all between-group comparisons). Cocaine craving was simultaneously reduced in the poly-substance group without protocol modification, consistent with ibogaine's multi-receptor mechanism.
Weekly alcohol consumption decreased 93% from baseline (45.2 standard units → 3.1 units at 90 days). Among the ~10% of patients who reported any alcohol use at follow-up, consumption was limited to social/occasional patterns well below hazardous thresholds (< 14 units/week).
No seizure events during or following treatment. The benzodiazepine bridge protocol (administered to 38% of patients with elevated withdrawal risk) effectively managed the GABAergic withdrawal component without interfering with ibogaine's therapeutic mechanism. Hepatic function improved (mean ALT decrease 18%) from baseline to Day 30 in patients with elevated baseline liver enzymes.
Clinical Protocol
14-Day Alcohol Treatment Protocol
Medical Screening. Liver Panel, Cardiac Evaluation & History
All alcohol dependency candidates undergo comprehensive pre-treatment medical screening including a full metabolic panel with liver function tests (ALT, AST, GGT, bilirubin), complete blood count, renal function, electrolytes, coagulation studies, and a 12-lead EKG. Candidates with QTc prolongation beyond accepted thresholds, Child-Pugh Class C hepatic impairment, or active hepatic encephalopathy are not accepted. Alcohol consumption history, prior withdrawal severity, and seizure history are documented in detail.
Supervised Alcohol Cessation with Benzodiazepine Bridge if Indicated
Patients with CIWA-Ar scores or histories suggesting significant withdrawal risk undergo a supervised cessation period with a benzodiazepine bridge protocol. This medically-managed taper reduces the risk of withdrawal seizures and delirium tremens while stabilizing the patient's neurological baseline ahead of ibogaine administration. Patients with mild-to-moderate withdrawal profiles may proceed without a benzodiazepine bridge following physician assessment.
Individualized Ibogaine Dosing Protocol
Our medical director designs a personalized ibogaine dosing protocol based on body weight, hepatic function, withdrawal severity history, poly-substance profile, and therapeutic goals. Alcohol dependency protocols typically incorporate a test dose followed by the primary therapeutic dose, with additional supportive alkaloids where clinically indicated. Patients with significant hepatic involvement receive adjusted protocols with enhanced monitoring.
Treatment at MindScape Retreat, Cozumel
Ibogaine is administered in our medically-equipped sanctuary on Cozumel Island under continuous physician and nursing supervision, with cardiac monitoring throughout the treatment session. The therapeutic environment is designed to support deep introspective processing. essential to the integration of behavioral and psychological patterns that sustain alcohol dependency beyond the neurochemical dimension.
Integration Therapy, Relapse Prevention & 90-Day Aftercare
Each patient departs with an individualized integration and relapse prevention plan. Integration focuses on identifying and restructuring the psychological triggers, relational dynamics, and stress patterns that have sustained alcohol use. We provide referrals to integration-trained therapists, access to peer support frameworks, and scheduled clinical check-ins at 30, 60, and 90 days post-treatment. Patients requiring ongoing pharmacological support (naltrexone, acamprosate) receive prescriptions and monitoring.
Frequently Asked Questions
Questions About Ibogaine for Alcohol Dependency
Supporting Literature & Citations
Freedom From Alcohol Is a Neurobiological Possibility
If alcohol dependency has resisted prior treatment attempts, ibogaine may offer the neurological reset that willpower and conventional therapy alone cannot provide. Our medical team evaluates every candidate individually and provides honest guidance on whether ibogaine is the right path for your situation.
Request a Confidential Evaluation